Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | AURKA | O14965 | 6/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528830 | 0.94 | AURKA (0.38) | KMT2AALDH1A1AURKARPS6KB1MAPT | |
| SCHEMBL2527048 | 0.91 | AURKA (0.35) | KMT2AALDH1A1AURKARPS6KB1MAPT | |
| SCHEMBL2526628 | 0.91 | AURKA (0.39) | KMT2AAURKARPS6KB1MAPTGPR88 | |
| SCHEMBL2527415 | 0.90 | AURKA (0.37) | KMT2AAURKARPS6KB1MAPTPOLB | |
| SCHEMBL2533520 | 0.90 | AURKA (0.35) | AURKARPS6KB1GPR88S1PR3 | |
| SCHEMBL2530772 | 0.90 | KMT2A (0.35) | KMT2AALDH1A1AURKARPS6KB1MAPT | |
| SCHEMBL2533255 | 0.90 | AURKA (0.35) | ALDH1A1AURKARPS6KB1MAPTGPR88 | |
| SCHEMBL2531074 | 0.90 | AURKA (0.35) | KMT2AALDH1A1AURKARPS6KB1MAPT | |
| SCHEMBL2527508 | 0.89 | HPGD (0.45) | KMT2AALDH1A1AURKARPS6KB1MAPT | |
| SCHEMBL2527495 | 0.89 | AURKA (0.34) | AURKARPS6KB1GPR88S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039501-B2 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2011-10-18 | — | — | US | disclosed |
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | HRH1, HRH3, HRH2 | KMT2A 2317/4885ALDH1A1 3248/4885AURKA 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.